RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Summary

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

Timeline

Start

2020-11-15

Primary completion

2021-11-15

Completion

2022-11-15

Drugs

Indications